IDENTIFICATION OF POTENTIAL PPARγ AGONIST SIMILAR TO PHYTOCHEMICAL MAGNOLOL

Main Article Content

SANA SHAFI
JEENA GUPTA

Abstract

Cis-Hinokiresinol or (z) -Hinokiresinol is a lignan found in Anemarrhena asphodeloides. It has also been investigated for its anti-inflammatory property using both in vitro and in vivo studies. Researchers have conducted many studies in order to develop relationship between various inflammation mediators and Type 2 diabetes mellitus (T2DM). Therefore, the anti-inflammatory effect of Hinokiresinol can be linked for its role in diabetes. In this study, we tried to explore the binding affinity of hinokiresinol with the nuclear receptor PPARγ, an important therapeutic target for type 2 diabetes. Hinokiresinol was found to have the structural similarity with natural PPARγ agonist, magnolol, a reported phytochemicals having potential effect in Type 2 diabetes. Magnolol was used as a query molecule for data mining and similarity searching. Molecular docking studies revealed that the affinity score of Hinokiresinol was higher, -10.2 (kcal/mol), than that of the standard magnolol -8.2 (kcal/mol). Also, Hinokiresinol have similar interaction profile, binding the same active site with at least one common interacting amino acid residue PHE 282. The ADME properties also suggest that Hinokiresinol can be a good candidate for further exploration. Our study recommends Hinokiresinol as potential PPAR gamma agonists and pharmaceutical lead molecule for further molecular dynamic studies as well as in vitro and in vivo studies. To best of our knowledge, this is the first report highlighting the PPARγ agonistic activity of Hinokiresinol.

Keywords:
Hinokiresinol, PPARγ, molecular docking, ADME

Article Details

How to Cite
SHAFI, S., & GUPTA, J. (2021). IDENTIFICATION OF POTENTIAL PPARγ AGONIST SIMILAR TO PHYTOCHEMICAL MAGNOLOL. PLANT CELL BIOTECHNOLOGY AND MOLECULAR BIOLOGY, 22(35-36), 397-409. Retrieved from https://www.ikprress.org/index.php/PCBMB/article/view/6965
Section
Short Research Article

References

Kwon J, Kondaji G, Song S, Kim C, Lee K, Kim WK, Choi Y. Synthesis of naturally occurring norlignan (±)-nyasol. Bulletin of the Korean Chemical Society. 2013;34(4): 1247-1249.

Park HJ, Lee JY, Moon SS, Hwang BK. Isolation and anti-oomycete activity of nyasol from Anemarrhena asphodeloides rhizomes. Phytochemistry. 2003;64(5):997-1001.

Kawasaki T, Yamauchi T. Saponins of Timo (????:Anemarrhenae Rhizoma). II. Structure of Timosaponin A-III. Chemical and Pharmaceutical Bulletin. 1963;11(10): 1221-1224.

Jung BS, Shin MK. In Hyang Yak Dae Sa Jeon, Young Lim Sa: Seoul. Korea. 1990; 234.

Song MC, Yang HJ, Myun-Ho B, Kim DK, Jeong TS, Kim JP, Baek NI. Antioxidant and antiatherogenic activity ofcis-hinokiresinol from Trapapseudoincisa. Archives of Pharmacal Research. 2007; 30(11):1392.

Lim H, Nam JW, Seo EK, Kim YS, Kim HP. (-)-Nyasol (cis-hinokiresinol), a norneolignan from the rhizomes of Anemarrhena asphodeloides, is a broad spectrum inhibitor of eicosanoid and nitric oxide production. Archives of Pharmacal Research. 2009;32(11):1509.

Jeong SJ, Ahn NH, Kim YC, Inagaki M, Miyamoto T, Higu20chi R. Norlignans with hyaluronidase inhibitory activity from Anemarrhena asphodeloides. Planta Medica. 1999;65(04):367-368.

Jeong SJ, Higuchi R, Ono M, Kuwano M, Kim YC, Miyamoto T, cis-Hinokiresinol, a norlignan from Anemarrhena asphodeloides, inhibits angiogenic response in vitro and in vivo. Biol. Pharm. Bull. 2003;26:1721-1724.

Lee HJ, Ryu JH. Hinokiresinol: a novel inhibitor of LTB4 binding to the human neutrophils. Planta Medica. 1999;65(4): 391.

Bae E, Park E, Yang H, Baek N, Kim D. Hinokiresinol inhibits IgE-induced mouse passive cutaneous anaphylaxis reaction. Planta Medica. 2006;72(14):1328.

Cohen I. U.S. Patent Application No. 12/484,067; 2009.

Minami E, Taki M, Takaishi S, Iijima Y, Tsutsumi S, Akiyama T. Stereochemistry of cis-and trans-hinokiresinol and their estrogen-like activity. Chemical and Pharmaceutical Bulletin. 2000;48(3):389-392.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3): 327-334.

Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812-817.

Shimabukuro M, Ohneda M, Lee Y, Unger RH. Role of nitric oxIDe in obesity-induced beta cell disease. The Journal of clinical Investigation. 1997;100(2):290-295.

Perreault M, Marette A. Targeted disruption of inducible nitric oxIDe synthase protects against obesity-linked insulin resistance in muscle. Nature Medicine. 2001;7(10):1138.

Laudet V, Hänni C, Coll J, Catzeflis F, Stéhelin D. Evolution of the nuclear receptor gene superfamily. The EMBO Journal. 1992;11(3):1003-1013.

Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, Vidal-Puig A. The organization, promoter analysis, and expression of the human PPARγ gene. Journal of Biological Chemistry. 1997; 272(30):18779-18789.

Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Research. 2000;60(4):1129- 1138.

Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Schuster D. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochemical Pharmacology. 2014;92(1):73-89.

Choi SS, Cha BY, Lee YS, Yonezawa T, Teruya T, Nagai K, Woo JT. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Life Sciences. 2009;84(25-26):908-914.

Martin YC, Kofron JL, Traphagen LM. Do structurally similar molecules have similar biological activity?. Journal of Medicinal Chemistry. 2002;45(19):4350-4358.

Kalyaanamoorthy S, Chen YPP. Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes. Biochimicaet Biophysica Acta (BBA)-Proteins and Proteomics. 2013; 1834(1):317-328.

Mandlik V, Singh S. Molecular docking and molecular dynamics simulation study of inositol phosphorylceramide synthase–inhibitor complex in leishmaniasis: Insight into the structure based drug design. F1000 Research. 2016;5.

Yuriev E, Agostino M, Ramsland PA. Challenges and advances in computational docking: 2009 in review. Journal of Molecular Recognition. 2011;24(2):149-164.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009;30(16):2785-2791.

Umesh HR, Ramesh KV, Devaraju KS. Molecular docking studies of phytochemicals against trehalose–6–phosphate phosphatases of pathogenic microbes. Beni-Suef University Journal of Basic and Applied Sciences. 2020;9(1): 1-14.

Kaur P, Bhat ZR, Bhat S, Kumar R, Kumar R, Tikoo K, Khatik GL. Synthesis and evaluation of new 1, 2, 4-oxadiazole based trans-acrylic acid derivatives as potential PPAR-alpha / gamma dual agonist. Bioorganic Chemistry. 2020;100:103867.

Daina A, Zoete V. A boiled‐egg to predict gastrointestinal absorption and brain penetration of small molecules. Chem Med Chem. 2016;11(11):1117.

Lipinski C. A; Lombardo, F.; Dominy, BW; Feeney, PJ Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001;46(1-3):3.

Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. International Scholarly Research Notices; 2012.

Ottaviani G, Gosling DJ, Patissier C, Rodde S, Zhou L, Faller B. What is modulating solubility in simulated intestinal fluids?. European Journal of Pharmaceutical Sciences. 2010;41(3-4):452-457.

Finch A, Pillans P. P-glycoprotein and its role in drug-drug interactions. Aust Prescr. 2014;37(4):137-139.

Szakács G, Váradi A, Özvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discovery Today. 2008;13(9-10):379-393.

Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews. 1995;27(3):397-417.

Testa B, Kraemer SD. The biochemistry of drug metabolism – an introduction - Testa - 2007 - Chemistry & Biodiversity - Wiley Online Library. Chem. Biodivers; 2007.

Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry. 1999;1(1):55-68.

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry. 2002;45(12): 2615-2623

Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry. 2000;43(21):3867-3877.

Muegge I, Heald SL, Brittelli D. Simple selection criteria for drug-like chemical matter. Journal of Medicinal Chemistry. 2001;44(12):1841-1846.

Pliska V, Testa B, van de Waterbeemd H. In Lipophilicity in Drug Action and Toxicology 1–6 (Wiley-VCH Verlag GmbH; 1996.

Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opinion on Drug Discovery. 2012; 7(10):863-875.